Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Cash from Operations (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Cash from Operations data on record, last reported at 44780000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 215.05% year-over-year to 44780000.0; the TTM value through Dec 2025 reached 1143000.0, changed N/A, while the annual FY2025 figure was 83155000.0, 133.91% up from the prior year.
  • Cash from Operations reached 44780000.0 in Q4 2025 per CAI's latest filing, down from 62425000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 62425000.0 in Q3 2025 and bottomed at 69427000.0 in Q3 2024.